PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21725799-0	2011	Validation of quinidine as a probe substrate for the in vitro P-gp inhibition assay in Caco-2 cell monolayer.	Quinidine	14-23	phosphoglycolate phosphatase	Homo sapiens	62-66	
24947467-2	2014	For five P-gp substrates (indinavir, quinidine, loperamide, paclitaxel, and verapamil) and one nonsubstrate (diazepam), in vitro P-gp transport activities were determined by measuring transcellular transport across monolayers of cynomolgus monkey P-gp-transfected LLC-PK1 and parental cells.	Quinidine	37-46	phosphoglycolate phosphatase	Homo sapiens	129-133	
24947467-2	2014	For five P-gp substrates (indinavir, quinidine, loperamide, paclitaxel, and verapamil) and one nonsubstrate (diazepam), in vitro P-gp transport activities were determined by measuring transcellular transport across monolayers of cynomolgus monkey P-gp-transfected LLC-PK1 and parental cells.	Quinidine	37-46	phosphoglycolate phosphatase	Homo sapiens	129-133	
23976943-12	2013	We also find that P-gp substrates with relatively low passive permeability such as digoxin, loperamide and vinblastine kinetically require basolateral uptake transport over that allowed by +GF120918 passive permeability, while highly permeable P-gp substrates such as amprenavir, quinidine, ketoconazole and verapamil do not, regardless of whether they actually use the basolateral transporter.	Quinidine	280-289	phosphoglycolate phosphatase	Homo sapiens	18-22	
21725799-1	2011	Although quinidine has been recommended as a probe substrate for the P-gp inhibition assay using Caco-2 cell monolayer, it has not been studied widely in the in vitro system.	Quinidine	9-18	phosphoglycolate phosphatase	Homo sapiens	69-73	
21725799-2	2011	In the present investigation, in vitro permeability studies using Caco-2 cell monolayer were carried out in order to optimize and validate quinidine as a P-gp probe substrate.	Quinidine	139-148	phosphoglycolate phosphatase	Homo sapiens	154-158	
21725799-6	2011	Overall, quinidine was found to be a good probe substrate for routine use to assess the in vitro inhibitory potency of NCEs on Pgp-mediated transport.	Quinidine	9-18	phosphoglycolate phosphatase	Homo sapiens	127-130	
19248230-8	2009	Concentration dependent decrease of this secretion was obtained by the P-gp inhibitors verapamil, erythromycin and quinidine, while no effect was evident by the MRP2 inhibitor MK-571 and the BCRP inhibitor FTC, indicating that P-gp is the transporter mediates the intestinal efflux of cimetidine and famotidine.	Quinidine	115-124	phosphoglycolate phosphatase	Homo sapiens	71-75	
20196146-5	2011	Rhodamine assay also revealed that hydrocinchonine, cinchonine, and quinidine effectively enhanced the accumulation of a P-gp substrate, rhodamine in TAX-treated MES-SA/DX5 cells compared with TAX-treated control.	Quinidine	68-77	phosphoglycolate phosphatase	Homo sapiens	121-125	
20196146-6	2011	In addition, hydrocinchonine, cinchonine, and quinidine effectively cleaved poly (ADP-ribose) polymerase (PARP), activated caspase-3, and downregulated P-gp expression as well as increased sub-G1 apoptotic portion in TAX-treated MES-SA/DX5 cells.	Quinidine	46-55	phosphoglycolate phosphatase	Homo sapiens	152-156	
22028772-9	2011	The P-gp efflux rate constants for quinidine and digoxin were about 3-fold smaller than reported ATP hydrolysis rate constants from P-gp proteoliposomes.	Quinidine	35-44	phosphoglycolate phosphatase	Homo sapiens	4-8	
22028772-9	2011	The P-gp efflux rate constants for quinidine and digoxin were about 3-fold smaller than reported ATP hydrolysis rate constants from P-gp proteoliposomes.	Quinidine	35-44	phosphoglycolate phosphatase	Homo sapiens	132-136	
19816852-8	2010	The efflux ratio for quinidine (100 nm) alone was 10.8, which reduced to less than 2 in the presence of the classical P-gp inhibitors verapamil and ketoconazole (100 mum each).	Quinidine	21-30	phosphoglycolate phosphatase	Homo sapiens	118-122	
15501934-9	2005	For three P-gp substrates (amprenavir, loperamide, and quinidine), we have successfully fitted the elementary rate constants, i.e., drug association to P-gp from the apical membrane inner monolayer, drug dissociation back into the apical membrane inner monolayer, and drug efflux from P-gp into the apical chamber, as well as the density of efflux active P-gp.	Quinidine	55-64	phosphoglycolate phosphatase	Homo sapiens	10-14	
15501934-9	2005	For three P-gp substrates (amprenavir, loperamide, and quinidine), we have successfully fitted the elementary rate constants, i.e., drug association to P-gp from the apical membrane inner monolayer, drug dissociation back into the apical membrane inner monolayer, and drug efflux from P-gp into the apical chamber, as well as the density of efflux active P-gp.	Quinidine	55-64	phosphoglycolate phosphatase	Homo sapiens	152-156	
15501934-9	2005	For three P-gp substrates (amprenavir, loperamide, and quinidine), we have successfully fitted the elementary rate constants, i.e., drug association to P-gp from the apical membrane inner monolayer, drug dissociation back into the apical membrane inner monolayer, and drug efflux from P-gp into the apical chamber, as well as the density of efflux active P-gp.	Quinidine	55-64	phosphoglycolate phosphatase	Homo sapiens	152-156	
15501934-9	2005	For three P-gp substrates (amprenavir, loperamide, and quinidine), we have successfully fitted the elementary rate constants, i.e., drug association to P-gp from the apical membrane inner monolayer, drug dissociation back into the apical membrane inner monolayer, and drug efflux from P-gp into the apical chamber, as well as the density of efflux active P-gp.	Quinidine	55-64	phosphoglycolate phosphatase	Homo sapiens	152-156	
15266218-7	2004	These values were also comparable with the inhibitory effect of quinidine in Caco-2 cells, a well-known inhibitor of P-gp, on ritonavir efflux from Caco-2 cells.	Quinidine	64-73	phosphoglycolate phosphatase	Homo sapiens	117-121	
26354948-6	2015	At clinically relevant quinidine plasma concentrations, P-gp inhibition resulted in a 60% increase in (11)C-radioactivity distribution across the human BBB as measured by the brain extraction ratio (ER) of (11)C-radioactivity.	Quinidine	23-32	phosphoglycolate phosphatase	Homo sapiens	56-60	
26354948-8	2015	Although our findings demonstrated that quinidine did not completely inhibit P-gp at the human BBB, it has the potential to produce clinically significant CNS drug interactions with P-gp substrate drugs that exhibit a narrow therapeutic window and are significantly excluded from the brain by P-gp.	Quinidine	40-49	phosphoglycolate phosphatase	Homo sapiens	182-186	
26354948-8	2015	Although our findings demonstrated that quinidine did not completely inhibit P-gp at the human BBB, it has the potential to produce clinically significant CNS drug interactions with P-gp substrate drugs that exhibit a narrow therapeutic window and are significantly excluded from the brain by P-gp.	Quinidine	40-49	phosphoglycolate phosphatase	Homo sapiens	182-186